樂
樂觀
樂觀 · 25%EXOZ
$12.90
情境價格
$4.400
+0.311 (+7.06%)收盤時
Loading chart…
- 最高
- 4.585
- 開盤
- 4.190
- 成交量加權均價
- 4.37
- 成交量
- 10.79K
- 市值
- —
- 最低
- 4.110
- 成交金額
- 47.09K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
AI 分析 of eXoZymes Inc (EXOZ)
買進Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
估值指標
eXoZymes Inc（EXOZ）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 EXOZ 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.506-24seekingalphaeXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- 8.506-08seekingalpha
eXoZymes Prices Public Offering to Raise $5.33 Million
9.504-07Yahoo FinanceMDB Capital Holdings Earnings Outlook
9.504-01Yahoo FinanceEXoZymes Inc Earnings Report Analysis and Outlook
- 9.503-31seekingalpha
eXoZymes Reports Increased FY Net Loss and Rising Expenses
EXOZ 常見問題 —— 由 Alphio AI 解答
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. It operates in the Healthcare sector.
Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。